Vania Aikawa

TL;DR: It is found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration, indicating that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19

TL;DR: Preclinical studies show potent activity of CART33 and indicate that transient expression of anti-CD33 CAR by RNA modification could be used in patients to avoid long-term myelosuppression.

TL;DR: This case highlights the utility of comprehensive molecular testing in the diagnosis of NSCLC and identifies a KRAS Q22K mutation and frameshift mutations in the genes encoding serine/threonine kinase 11 (STK11) and ataxia telangiectasia mutated serine-threonin kinase (ATM) by next-generation sequencing.

TL;DR: A case of donor derived 20q11.2 deletion in a male patient who received an allogeneic HSCT from his HLA-identical sister for the treatment of his chronic lymphocytic leukemia and there has been no evidence of an associated hematologic neoplasm in either the donor or recipient.

TL;DR: This data indicates that conventional chemotherapy may not be an effective treatment for central giant cell granuloma, and the next step is to investigate the role of Epstein-Barr virus in the development of the disease.